Synonym
XL228; XL-228; XL 228
IUPAC/Chemical Name
N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-((3-isopropylisoxazol-5-yl)methyl)-6-(4-methylpiperazin-1-yl)pyrimidine-2,4-diamine
InChi Key
ALKJNCZNEOTEMP-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H31N9O/c1-14(2)17-10-16(32-29-17)13-23-22-25-19(24-20-11-18(27-28-20)15-4-5-15)12-21(26-22)31-8-6-30(3)7-9-31/h10-12,14-15H,4-9,13H2,1-3H3,(H3,23,24,25,26,27,28)
SMILES Code
CN(CC1)CCN1C2=NC(NCC3=CC(C(C)C)=NO3)=NC(NC4=NNC(C5CC5)=C4)=C2
Appearance
White solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
437.54
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Edilova MI, Law JC, Zangiabadi S, Ting K, Mbanwi AN, Arruda A, Uehling D, Isaac M, Prakesch M, Al-Awar R, Minden MD, Abdul-Sater AA, Watts TH. The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia. Oncoimmunology. 2021 Sep 23;10(1):1943234. doi: 10.1080/2162402X.2021.1943234. PMID: 34589290; PMCID: PMC8475556.
2: Patel A, Li L, Anand A. Systematic review: functional outcomes and complications of intramedullary nailing versus plate fixation for both-bone diaphyseal forearm fractures in children. Injury. 2014 Aug;45(8):1135-43. doi: 10.1016/j.injury.2014.04.020. Epub 2014 May 2. PMID: 24845408.
3: Li L, McKee A. Dental rolls for tendon repair practice. Ann R Coll Surg Engl. 2013 Mar;95(2):155. doi: 10.1308/rcsann.2013.95.2.155a. PMID: 23485002; PMCID: PMC4098587.
4: Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev. 2012 Jun;38(4):292-302. doi: 10.1016/j.ctrv.2011.07.008. Epub 2011 Sep 9. PMID: 21907495.
5: King ER, Wong KK. Insulin-like growth factor: current concepts and new developments in cancer therapy. Recent Pat Anticancer Drug Discov. 2012 Jan;7(1):14-30. doi: 10.2174/157489212798357930. PMID: 21875414; PMCID: PMC3724215.
6: Schenone S, Brullo C, Musumeci F, Botta M. Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin Investig Drugs. 2010 Aug;19(8):931-45. doi: 10.1517/13543784.2010.499898. PMID: 20557276.
7: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Oct;30(8):643-72. PMID: 19088949.
8: Noronha G, Cao J, Chow CP, Dneprovskaia E, Fine RM, Hood J, Kang X, Klebansky B, Lohse D, Mak CC, McPherson A, Palanki MS, Pathak VP, Renick J, Soll R, Zeng B. Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem. 2008;8(10):905-21. doi: 10.2174/156802608784911635. PMID: 18673174.
